Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients wi...
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT
About this item
Full title
Author / Creator
Grövdal, M , Nahi, H , Gahrton, G , Liwing, J , Waage, A , Abildgaard, N , Pedersen, P T , Hammerstrøm, J , Laaksonen, A , Bazia, P , Terava, V , Ollikainen, H , Silvennoinen, R , Putkonen, M , Anttila, P , Porkka, K and Remes, K
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is the most common first-line treatment for patients with multiple myeloma (MM) under 65 years of age. A second ASCT at first relapse is frequently used but is challenged by the use of novel drugs. We retrospectively studied the outcome of second-line treatment in MM pa...
Alternative Titles
Full title
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_514306
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_514306
Other Identifiers
ISSN
0268-3369
E-ISSN
1476-5365
DOI
10.1038/bmt.2015.39
